Canopy Growth to Strengthen Balance Sheet with Early Prepayments Set to Reduce Term Loan by US$50 Million; Annual Cash Interest Expense Expected to be Reduced by US$6.5 Million

Stock Information for TriSalus Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TriSalus Life Sciences Inc.

Canopy Growth Launches Claybourne Gassers Liquid Diamonds All-In-One Vapes in Canada, Expanding Footprint in High-Growth Vape Segment
Canopy Growth Expands Spectrum Therapeutics Portfolio in Australia with New Softgels
Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet
Canopy Growth to Report Second Quarter Fiscal 2026 Financial Results on November 7, 2025
Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders
Canopy Growth Announces DOJA as Dedicated Canadian Medical Facility
JP Brand Advisors and Canopy USA Form Strategic Partnership to Expand Hemp Beverage Distribution
Canopy Growth Corporation Announces Adjournment of Annual General and Special Meeting of Shareholders Due to Lack of Quorum

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.